JPMorgan Chase & Co. Has $336,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

JPMorgan Chase & Co. increased its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 220.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 100,517 shares of the company’s stock after buying an additional 69,167 shares during the period. JPMorgan Chase & Co. owned 0.13% of Trevi Therapeutics worth $336,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. American Century Companies Inc. boosted its stake in Trevi Therapeutics by 17.1% during the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after purchasing an additional 7,902 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Trevi Therapeutics by 217.6% in the second quarter. Dimensional Fund Advisors LP now owns 72,210 shares of the company’s stock valued at $215,000 after acquiring an additional 49,475 shares during the period. Hsbc Holdings PLC bought a new stake in shares of Trevi Therapeutics in the second quarter valued at approximately $61,000. The Manufacturers Life Insurance Company grew its stake in shares of Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after acquiring an additional 11,450 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Trevi Therapeutics during the third quarter worth $78,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TRVI. HC Wainwright increased their price target on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a report on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. B. Riley restated a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a research note on Monday, October 7th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday, January 8th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Trevi Therapeutics has an average rating of “Buy” and an average target price of $9.31.

Trevi Therapeutics Trading Up 1.0 %

NASDAQ TRVI opened at $3.90 on Friday. Trevi Therapeutics, Inc. has a 1-year low of $1.35 and a 1-year high of $4.68. The stock’s 50 day moving average is $3.65 and its two-hundred day moving average is $3.24. The company has a market capitalization of $299.78 million, a price-to-earnings ratio of -8.86 and a beta of 0.87.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter in the previous year, the company posted ($0.08) earnings per share. On average, analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.